Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Formal Collaboration Agreements between the University of Oxford and the Oxford Radcliffe Hospitals NHS Trust

The University of Oxford and the Oxford Radcliffe Hospitals NHS Trust have signalled their intention to cement and strengthen their collaboration in research, teaching and patient care by agreeing terms for a formal and legally-binding relationship.

There has been a long history of joint working between the University of Oxford and the NHS hospitals in Oxford, greatly benefitting both patients and the wider community.

 

Existing collaborations include the ambitious research programmes established through the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Oxford Radcliffe Hospitals NHS Trust (ORH) and at the Biomedical Research Unit in musculoskeletal disease at the Nuffield Orthopaedic Centre NHS Trust (NOC). These set the standard in translating science and research into new and better NHS clinical care.

The University and the Oxford Radcliffe Hospitals NHS Trust have agreed to formalise their relationship by entering into a Joint Working Agreement and a Trade Mark Licence. These will provide a formal structure and governance to the relationship between the two organisations, enhancing the ability to share ideas and activities and to function as a joint venture committed to the pursuit of excellence in patient care, research and education.

The intent is to complete these agreements at the same time as the ORH’s integration with the Nuffield Orthopaedic Centre NHS Trust, which is planned to take place later in the year (subject to approval by the Secretary of State for Health).

Professor Andrew Hamilton, Vice-Chancellor of Oxford University said: “We welcome this opportunity to strengthen our relationship with the hospitals further, forming the tight links which support the best teaching of medical students, excellence in medical research and the delivery of quality healthcare.

“The University has long worked closely with the Oxford Radcliffe Hospitals. These new agreements will recognise our strong mutual interests and will see us extend the way we work together, with benefits for the care which patients receive now and research on the treatments they may receive in the future.”

Sir Jonathan Michael, Chief Executive of the Oxford Radcliffe Hospitals NHS Trust, said: “The collaboration between the Oxford Radcliffe Hospitals and the University underpins the quality of the care that is provided to patients; to the delivery of high-quality research bringing innovation from the laboratory bench to the bedside; and the delivery of high-quality education and training of doctors. The decision by the Trust Board and the University Council to enter into these formal agreements reinforces this very important relationship.”

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.